Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Open Access
- 1 September 2014
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 147 (3), 618-627.e3
- https://doi.org/10.1053/j.gastro.2014.05.008
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceuticals International
This publication has 31 references indexed in Scilit:
- Crohn's diseaseThe Lancet, 2012
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Management of Crohn's Disease in AdultsThe American Journal of Gastroenterology, 2009
- Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?Gastroenterology, 2008
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Natalizumab Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Natalizumab for Active Crohn's DiseaseNew England Journal of Medicine, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002